Relationship of Body Adiposity with Platelet Function in Obese and Non-obese Individuals

Bukhari, Ishfaq A.; Habib, Syed Shahid; Alnahedh, Alaa; Almutairi, Futoon; Alkahtani, Lama; Alareek, Latefa A.; Assiri, Ghadah Asaad

doi:10.7759/cureus.6815

Cited by 4 publications

(4 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…32 Other studies, have also shown that obesity is associated with impaired responsiveness to ASA. 10,24,[33][34][35] Interestingly, although CRP and WBC counts were elevated in our highest BMI group suggesting an increased, basal inflammatory state in obese individuals, baseline ARU and TxB2 levels were equivalent in obese and non-obese individuals in our cohort. Thus, our data suggest that in healthy individuals, obesity is not associated with baseline platelet hyper-reactivity.…”

Section: Discussionmentioning

confidence: 52%

“…A post hoc analysis of the Aspirin in Reducing Events in the Elderly Trial (ASPREE) in patients ≥70 years of age without documented cardiovascular and cerebrovascular disease or high risk of bleeding found no association between low‐dose ASA cardiovascular disease events with body weight or other measures of body habitus 32 . Other studies, have also shown that obesity is associated with impaired responsiveness to ASA 10,24,33–35 …”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Prospective, randomized, controlled, trial to assessASADOSingby body mass index inHEalthyvolunteers (DOSEstudy)

et al. 2023

View full text Add to dashboard Cite

Study Objective: Aspirin (ASA) has demonstrated inconsistent results in primary prevention of cardiovascular disease (CVD). Guidelines are also inconsistent in the recommendation of routine ASA use for primary prevention of CVD, but advocate dosing as a "one-size-fits-all" approach.Design: An intention-to-treat, double-blind, randomized, controlled, clinical trial comparing three treatment arms of ASA 81, 325, and 500 mg daily dosed for 14 days were evenly randomized across the dosing categories to measure the impact of dosing by body mass index (BMI) (20-24.9, 25-29.9, ≥30 kg/m 2 ) on ASA anti-platelet effects.Setting: University Ambulatory Clinic.Patients: Healthy volunteers defined as individuals who were medication free without acute or chronic significant health problems.Intervention: Change in ASA reactivity unit (ARU), salicylate levels, and thromboxane B2 (TxB2) levels were measured across BMI dosing categories and time.Main Results: Fifty-four participants with a mean (±SD) age of 34.4 ± 10.9 years (M:F; 23:31) completed the study. Baseline ARU and TxB2 levels were not significantly different between obese and non-obese individuals. BMI was not a predictor of platelet inhibition. There was no interaction between gender and platelet activation at baseline or following ASA treatment. ASA 81 mg was associated with a lower ARU response (approximate 50% lower response) than either the 325-mg or the 500-mg doses of ASA. TxB2 and salicylate levels exhibited lower trends at 81 mg compared with higher doses. Conclusions:In healthy male and female participants administered ASA for 14 days, obesity is not associated with increased basal platelet activation or ASA resistance.ASA 81 mg was significantly less effective in reducing platelet aggregation compared with ASA 325 and 500 mg, independent of BMI.

show abstract

Section: Discussionmentioning

confidence: 52%

Section: Discussionmentioning

confidence: 99%

Prospective, randomized, controlled, trial to assessASADOSingby body mass index inHEalthyvolunteers (DOSEstudy)

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Here, it was observed that the platelet count, the platelet volume, and the MPR index cycled for the normal weight group but were planar for the obese group. Adiposity has been associated with thrombotic changes by promoting platelet activation [49]. However, other studies have not established whether elevated platelet counts in obese individuals are associated with platelet activation [16].…”

Section: Discussionmentioning

confidence: 99%

Obesity attenuates the beneficial effect of an intrauterine infusion of autologous platelet-rich plasma during in vitro fertilization

Hernández-Melchor

2024

Am J Transl Res

View full text Add to dashboard Cite

Objective: To assess how obesity, normal weight (NW) versus overweight/obese (OW/OB), impacts plateletrich plasma's (PRP) effectiveness during in vitro fertilization and how obesity affects platelets during the menstrual cycle. Methods: Endometrial mean thickness (EMT), embryo implantation, and clinical pregnancy were assessed using a self-controlled retrospective study that enrolled 59 patients with two failed cycles and treated with autologous PRP (three-dose scheme). The NHANES dataset was used to assess platelet changes during the menstrual cycle, using the mean platelet volume to platelet count ratio (MPR) index. The COSINOR packages for R were used to determine rhythmicity. Results: PRP treatments significantly improved the EMT (2.5 ± 1.4 mm, P<0.001), unaffected by obesity. After the PRP treatment, one patient spontaneously became pregnant; therefore, 58 patients underwent embryo transfer (62 cycles), of which in 39 cycles the embryos implanted (63.9%). This was a significant improvement from their previous cycle (vs. 22.6%, P<0.001). Clinical pregnancy also improved with the PRP treatment over the previous cycle (57.4% vs. 16.1%, P<0.001). When stratified by obesity, there was an appreciable decrease in embryo implantation and clinical pregnancy rates for the OW/OB group; nevertheless, the PRP treatment significantly improved embryo implantation and clinical pregnancy (P<0.05). A rhythm was observed with the MPR index (P<0.05) only for the NW group, suggesting that the platelets normally fluctuate during the menstrual cycle. Conclusion: PRP improved embryo implantation and clinical pregnancy rates; however, these beneficial effects were attenuated by obesity. PRP presumptively promoted a change in the uterine environment to mimic the normal findings associated with normal-weight women.

show abstract

“…Elevated platelet activation and aggregation are usually associated with obesity [19], but it should be borne in mind that most of the platelet activation studies related to obesity were performed in patients with already‐known cardiovascular diseases. Several studies conducted in non‐patient population showed no difference in platelet activation between non‐obese and obese individuals [20, 21]. Recently, it has been reported that there are platelet phosphorylation changes related to obesity, resulting in dysregulation of the main signalling pathways, including activation of platelets [22].…”

Section: Discussionmentioning

confidence: 99%

Aggregates in apheresis‐derived platelet concentrates: A 5‐year single‐centre experience

Vinković,

Hećimović,

Jukić

et al. 2024

Vox Sanguinis

View full text Add to dashboard Cite

Background and ObjectivesThe phenomenon of aggregates in apheresis‐derived platelet concentrates (APCs) has not yet been fully elucidated. Initially, visible aggregates (IVA) usually dissolve within 24 h after collection, but some persist till the end of the shelf life (persistent aggregates, PA). A study conducted at the Croatian Institute of Transfusion Medicine aimed to identify factors that influence the aggregate occurrence in APCs.Materials and MethodsWe conducted a cross‐sectional study for the 2018–2022 period and collected data on APCs with IVA. We analysed APCs discarded due to PA separately for two apheresis technologies and compared them to the control group.ResultsSignificantly more donations were discarded in the IVA group compared with the control group and total number of discarded APCs. A total of 205 APCs were discarded due to PA (14.7% of IVA APCs and 1.27% of all APCs collected). Amicus APCs with PA had a significantly lower platelet count and mean platelet volume. They were obtained by procedures with less anticoagulant used. In contrast to Amicus APCs, Haemonetics APCs with PA had a significantly higher platelet count. None of the donor‐related factors examined was predictive of PA.ConclusionAPCs with IVA are more often discarded, not only due to aggregates, but also for impairment of other quality control parameters. Type of apheresis technology, being one of the most common risk factors for IVA, was not confirmed as the main risk factor for PA. There seem to be some donor‐related causal factors.

show abstract

Relationship of Body Adiposity with Platelet Function in Obese and Non-obese Individuals

Cited by 4 publications

References 16 publications

Prospective, randomized, controlled, trial to assessASADOSingby body mass index inHEalthyvolunteers (DOSEstudy)

Prospective, randomized, controlled, trial to assessASADOSingby body mass index inHEalthyvolunteers (DOSEstudy)

Obesity attenuates the beneficial effect of an intrauterine infusion of autologous platelet-rich plasma during in vitro fertilization

Aggregates in apheresis‐derived platelet concentrates: A 5‐year single‐centre experience

Contact Info

Product

Resources

About